Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2019-12-18 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated December 18, 2019, announcing that bioMérieux has been selected as a supplier by the Fleming Fund to provide diagnostic equipment to strengthen antimicrobial resistance (AMR) surveillance in low- and middle-income countries. It details the partnership, the scope of work (equipping laboratories with specific systems), and provides background information on both bioMérieux and the Fleming Fund. This type of announcement, detailing a significant business development, partnership, or contract award, does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement. Since it is not a formal regulatory filing like a 10-K or a specific report like an AR or SR, and it is not a transcript (CT) or a management discussion (MDA), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that are not covered by the other specific codes.
2019-12-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 18, 2019, announcing that bioMérieux has been selected as a supplier for the Fleming Fund program to combat antimicrobial resistance in low-resource countries. It details the partnership, the scope of work (equipping labs with diagnostic systems), and provides background information on both bioMérieux and the Fleming Fund. This type of announcement, which communicates a significant business development, partnership, or strategic update, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format and content (a press release about a contract/program), RNS is the most appropriate general category for non-standard, material announcements that aren't explicitly ER, 10-K, or DIV. Since it is not a formal financial report (10-K, IR, MRQ) nor a specific management/governance document, RNS serves as the best fit for a material press release announcement.
2019-12-18 French
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is a 'Regulated Information – disclosure of trading in own shares' pursuant to European regulation no 596/2014 (MAR regulation). It details the purchase of the company's own shares over several days in December 2019, including aggregated daily volumes and detailed transaction logs. This activity directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance reports.
2019-12-12 English
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is a 'Regulated Information – disclosure of trading in own shares' pursuant to European regulation no 596/2014 (MAR regulation), detailing purchases of its own shares by bioMérieux between November 29 and December 5, 2019. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a director's dealing (DIRS), as it concerns the issuer itself.
2019-12-09 English
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 98% confidence The document explicitly states in the header: "Information Réglementée – déclaration de transactions sur actions propres" (Regulated Information – declaration of transactions on own shares). It further mentions compliance with European Regulation No 596/2014 (MAR) and details transactions on the company's own shares ('transactions réalisées sur ses actions propres') for a specific period (November 29 to December 5, 2019). This content directly corresponds to the definition of reporting insider/executive share transactions, which maps to the 'Director's Dealing' category (DIRS) or, more broadly, transactions in own shares (POS). Since the document details the company's own transactions (repurchases/acquisitions of own shares, often for employee plans as indicated by 'Couverture attribution salariés'), the most precise fit among the provided options is 'Transaction in Own Shares' (POS). While DIRS covers director trades, POS covers the company's own share transactions, which is what this filing is about.
2019-12-09 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is most closely aligned with general regulatory disclosures or specific capital structure updates. Given the options, it is a specific regulatory filing concerning share capital, but it doesn't fit perfectly into SHA (Share Issue/Capital Change) as it's a periodic disclosure of existing structure, nor DVA (Declaration of Voting Results) as it's a monthly count, not final results of a vote. However, since it is a mandatory disclosure related to share capital structure and voting rights, and it is not a full financial report or an earnings release, it falls under the general category of regulatory filings (RNS) or potentially a specific capital/financing update (CAP) if interpreted broadly. Given the specific nature of reporting voting rights monthly, it is a standard regulatory disclosure. Since there is no specific code for 'Monthly Voting Rights Disclosure', RNS (Regulatory Filings) is the most appropriate fallback for a mandatory, non-financial report regulatory notice. The document length is short (1669 chars), but it contains the full required information, not just an announcement of a report, thus it is not RPA.
2019-12-06 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.